ReviewEuropean journal of endocrinology2009
Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.
Review in European journal of endocrinology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 44 citations in OpenAlex.
- The 5-HTPsychopharmacology · 2018Trial
- Effects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers.Psychopharmacology · 2014Trial
- Antagonist-elicited cannabis withdrawal in humans.Journal of clinical psychopharmacology · 2011Trial
- A chemical genetic screen uncovers a small molecule enhancer of the N-acylethanolamine degrading enzyme, fatty acid amide hydrolase, in Arabidopsis.Scientific reports · 2017Article
- Malonylation of Glucosylated N-Lauroylethanolamine: A NEW PATHWAY THAT DETERMINES N-ACYLETHANOLAMINE METABOLIC FATE IN PLANTS.The Journal of biological chemistry · 2016Article
- Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.Endocrinology and metabolism clinics of North America · 2014Review
- Safety of antiobesity drugs.Therapeutic advances in drug safety · 2013Article
- Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents.Diabetologia · 2012Article
- Nonhuman primates and other animal models in diabetes research.Journal of diabetes science and technology · 2012Review
- Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds.Oncology letters · 2012Article
- Article
- To be or not to be--obese.Endocrinology · 2011Article
- Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities.Journal of pharmacy & bioallied sciences · 2011Article
- Pathophysiology and treatment options for cardiac anorexia.Current heart failure reports · 2011Review
- The cannabinoid type-1 receptor carboxyl-terminus, more than just a tail.Journal of neurochemistry · 2011Review
- Rise and fall of anti-obesity drugs.World journal of diabetes · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The endocannabinoid system has emerged as a significant player in the control of energy balance and metabolism, through its direct central and peripheral effects, as well as via its interaction with other appetite-regulating pathways. There is mounting evidence that the endocannabinoid system is overactive in obesity and were it possible to safely dampen-down the elevated endocannabinoid tone, lipid and carbohydrate profiles could be improved and weight loss induced. The series of randomised clinical trials showed reproducible beneficial effects on weight, HbA1c and lipid parameters, in addition to other cardiovascular risk factors. However, to date, clinical developments have been halted because of psychiatric side effects. Although recent evidence has highlighted the importance of an appetite-independent, peripheral mode of action, it is still unclear whether selectively blocking the peripheral system could potentially solve the problem of the central side effects, which thus far has led to the demise of the cannabinoid antagonists as useful pharmaceuticals. In this concise review, we summarise the data on the metabolic effects of the cannabinoid pathway and its antagonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.